Drug discovery is a high-risk, high-cost endeavor, with over 90% of candidates failing in clinical development. A significant proportion of these failures stem from unresolved biopharmaceutic challenges—poor solubility, limited permeability, transporter-mediated efflux, and extensive first-pass metabolism—which compromise a drug's absorption and bioavailability, rendering it ineffective in vivo. Traditional formulation and screening methods have proven inadequate for the modern pipeline of complex molecules. This review examines how the integration of artificial intelligence (AI)-driven predictive tools and innovative formulation technologies, such as 3D printing and biodegradable nanocarriers, is revolutionizing the approach to these age-old limitations, offering a pathway to more efficient and personalized drug development.
Biopharmaceutic Barriers to Drug Success
The journey of an oral drug from administration to systemic circulation is fraught with obstacles. First, poor aqueous solubility affects up to 90% of developmental candidates, preventing adequate dissolution in the gastrointestinal tract. The Biopharmaceutics Classification System (BCS) categorizes drugs based on solubility and permeability, guiding formulation strategy: Class II (low solubility, high permeability) and Class IV (low solubility, low permeability) drugs pose the greatest challenges. Second, even if dissolved, drugs face permeability barriers due to molecular size or hydrophilicity. Third, efflux transporters like P-glycoprotein and BCRP act as "cellular bouncers," actively extruding drugs from enterocytes, severely limiting absorption. Finally, extensive pre-systemic metabolism by cytochrome P450 enzymes, particularly CYP3A4, can drastically reduce bioavailability. These interconnected barriers are major contributors to late-stage attrition.
AI & Computational Modeling in Biopharmaceutics
AI and machine learning (ML) are transforming early-stage drug development by enabling accurate in silico prediction of absorption, distribution, metabolism, and excretion (ADME) properties. This shift from labor-intensive, low-throughput experimental screening to computational prediction allows for the early triaging of compounds with unfavorable biopharmaceutic profiles.
ADME Prediction Tools: Platforms like SwissADME, ADMETlab 2.0, and Deep-Pk utilize algorithms—from simple rule-based systems to complex deep learning graph neural networks—to predict solubility, permeability, transporter interactions, and metabolic hotspots with high accuracy. These tools help medicinal chemists design molecules with improved drug-like properties.
Transporter and Metabolism Prediction: AI models can predict affinities for efflux transporters and identify substrates for metabolic enzymes, flagging potential drug-drug interactions or poor bioavailability risks long before in vitro testing.
Integration with Drug Discovery: AI's role extends to target identification and structure-based design. Tools like AlphaFold provide high-accuracy protein structure predictions, facilitating virtual screening of massive compound libraries (e.g., ZINC22's billions of molecules) to identify optimal binders, as demonstrated by platforms like RosettaVS.
Modern Formulation Innovations
When molecular optimization alone is insufficient, advanced formulation technologies intervene to enhance delivery.
3D-Printed Pharmaceuticals: Additive manufacturing enables the creation of complex, personalized dosage forms. Techniques like fused deposition modeling and semi-solid extrusion can produce multi-drug tablets, tailor release profiles, and incorporate drugs into mesoporous materials to dramatically improve the dissolution rate of poorly soluble compounds. This paves the way for true personalized medicine, though clinical validation and regulatory pathways are still evolving.
Biodegradable Nanocarriers: Lipid-based and polymer-based (e.g., PLGA-PEG) nanoparticles encapsulate drugs, protecting them from degradation and enhancing solubility. They enable targeted delivery via passive (e.g., enhanced permeability and retention in tumors) or active (ligand-mediated) mechanisms, improving therapeutic efficacy while reducing systemic toxicity.
Regulatory Challenges and Implementation Strategies
The adoption of AI and novel formulations presents significant regulatory hurdles. AI models require high-quality, representative data to avoid bias and ensure generalizability. Regulatory agencies like the FDA are developing frameworks to govern AI use in drug development. For novel formulations, demonstrating consistent quality, scalable manufacturing, and long-term safety of materials (e.g., 3D-printing inks, nanocarrier components) is critical. Proactive engagement via programs like the FDA's Emerging Technology Program and adherence to Quality by Design (QbD) principles are key strategies for aligning innovation with regulatory expectations.
Limitations and Future Prospects
While promising, most AI tools and advanced formulations remain in preclinical or early-stage validation. Future efforts must focus on robust clinical translation, addressing data bias in AI, ensuring ethical use of patient data for personalization, and improving the economic feasibility of these technologies. The integration of AI with 3D printing and nanocarrier design holds particular promise for creating dynamic, patient-specific treatment regimens.
Conclusion
Biopharmaceutic barriers are a fundamental cause of drug development failure. A paradigm shift is underway, moving from empirical formulation to a predictive, integrated approach. AI-driven in silico tools allow for the early design of molecules with favorable ADME profiles, while modern formulation technologies like 3D printing and nanocarriers rescue promising compounds by overcoming delivery limitations. The convergence of these fields, guided by evolving regulatory science and ethical considerations, is forging a more efficient, personalized, and successful future for drug development.
Full text
https://xiahepublishing.com/2572-5505/JERP-2025-00025
The study was recently published in the Journal of Exploratory Research in Pharmacology .
Journal of Exploratory Research in Pharmacology (JERP) publishes original innovative exploratory research articles, state-of-the-art reviews, editorials, short communications that focus on novel findings and the most recent advances in basic and clinical pharmacology, covering topics from drug research, drug development, clinical trials and application.
